Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | not yet recruiting | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691632 | Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 9, 2026 |
| clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 48 | Shanghai Changzheng HospitalOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 50 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07688291 | A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy | not yet recruiting | Phase 2 | 40 | Beijing GoBroad HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688577 | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Xilio Development, Inc.INDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck(ZANACC) | not yet recruiting | Phase 2 | 51 | UNICANCEROTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07684170 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 58 | Compass TherapeuticsINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07685197 | Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC | not yet recruiting | Phase 2 | 100 | Zhou ChengzhiOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | not yet recruiting | Phase 2 | 46 | Zhifeng Zhao, PhDOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | not yet recruiting | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07678580 | Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 50 | Tang-Du HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | not yet recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07662811 | SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 396 | Shanghai Chest HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | not yet recruiting | Phase 2 | 28 | GOG FoundationNETWORK | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07670715 | Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma(PANDA) | not yet recruiting | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | not yet recruiting | Phase 1 / Phase 2 | 76 | Telomir Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 23, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07659678 | CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 90 | Washington University School of MedicineOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07661173 | A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 154 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 2 / Phase 3 | 465 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer(ESCC-PT) | not yet recruiting | Phase 2 / Phase 3 | 90 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07358689 | Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07612007 | HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization | not yet recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07146230 | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2(SPRINT 2) | not yet recruiting | Phase 2 | 52 | Montefiore Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07303283 | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 140 | Kai HuOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | not yet recruiting | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07636772 | A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 132 | AkesoINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | not yet recruiting | Phase 2 | 10 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07632209 | Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment(Aurora003) | not yet recruiting | Phase 2 | 46 | Yayi HeOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07630077 | Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jun 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2026source: clinicaltrials